悦康药业(688658.SH)：注射用YKYY031用于开展晚期实体瘤临床试验获得批准

智通财经2025-12-12

智通财经APP讯，悦康药业(688658.SH)发布公告，公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(以下简称“NMPA”)核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗，拟用于晚期实体瘤的治疗。项目采用基于公司自主知识产权的新型阳离子脂质YK-009组成的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590740985?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-12 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590740985","market":"fut","top_or_hot":-1,"title":"悦康药业(688658.SH)：注射用YKYY031用于开展晚期实体瘤临床试验获得批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(以下简称“NMPA”)核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗，拟用于晚期实体瘤的治疗。项目采用基于公司自主知识产权的新型阳离子脂质YK-009组成的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1380927.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>悦康药业(688658.SH)：注射用YKYY031用于开展晚期实体瘤临床试验获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n悦康药业(688658.SH)：注射用YKYY031用于开展晚期实体瘤临床试验获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-12 17:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1380927.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，悦康药业(688658.SH)发布公告，公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(以下简称“NMPA”)核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗，拟用于晚期实体瘤的治疗。项目采用基于公司自主知识产权的新型阳离子脂质YK-009组成的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1380927.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688658","symbol_name":"悦康药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1380927.html","article_id":"2590740985","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590740985","pubTimestamp":1765531478,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，悦康药业 发布公告，公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗，拟用于晚期实体瘤的治疗。注射用YKYY031临床前研究充分证实其具备显著的有效性与良好的安全性，优势突出。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"Yuekang Pharmaceutical (688658. SH): YKYY031 for injection was approved for clinical trials of advanced solid tumors","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1.5},"content_text":"智通财经APP讯，悦康药业(688658.SH)发布公告，公司全资子公司北京悦康科创医药科技股份有限公司、杭州天龙药业有限公司于近日获得国家药品监督管理局(以下简称“NMPA”)核准签发的关于同意注射用YKYY031用于开展晚期实体瘤的《药物临床试验批准通知书》。注射用YKYY031是一种通用型mRNA肿瘤疫苗，拟用于晚期实体瘤的治疗。项目采用基于公司自主知识产权的新型阳离子脂质YK-009组成的脂质纳米颗粒(LNP)递送系统，该系统具备递送效率高、安全性良好的特点。注射用YKYY031所含的mRNA序列编码由多个在实体瘤组织中高表达的肿瘤相关抗原(TAA)及特异性表达的肿瘤特异性抗原(TSA)表位肽串联组成的多肽抗原序列。该疫苗递送至体内后，可诱导机体产生针对这些抗原的特异性杀伤T细胞，抑制肿瘤细胞生长。项目核心序列专利及递送系统专利已获得国家知识产权局发明专利授权，并同步完成了国际专利申请，公司享有全球独占权益。注射用YKYY031临床前研究充分证实其具备显著的有效性与良好的安全性，优势突出。有效性方面，注射用YKYY031可诱导显著且持久的肿瘤抗原特异性T细胞免疫反应，并在多种给药方案下表现出明确的抗肿瘤活性，且与抗PD-1抗体联合使用可进一步增强疗效。安全性方面，毒理学研究显示安全性良好，存在宽泛治疗窗口，为临床应用奠定坚实基础。稳定性方面，本品采用先进的LNP冻干工艺，能够彻底突破mRNA产品对超低温冷链的依赖，大幅降低运输和储存成本，提高本品可及性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590740985","isCrawlerRequest":true}